


Azelaprag

Chemical Properties

CAS No. :	2049980-18-7
Formula:	C ₂₅ H ₂₉ N ₇ O ₄ S
Molecular Weight:	523.61
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Azelaprag (Example 263.0) is a candidate active molecule (EC ₅₀ = 0.32 nM) for an apelin receptor agonist. Azelaprag can be used to treat nervous system diseases, cardiovascular diseases.
Targets(IC ₅₀)	Apelin receptor
In vivo	METHODS: To investigate the effect of Azelaprag on cardiac function, Azelaprag (1mg/kg/min) was infused intravenously at an acute time point in a rat model of impaired metabolic function. RESULTS: Azelaprag increased cardiac reserve during Dobutamine challenge in a metabolically impaired rat model. [1]

Solubility Information

Solubility	DMSO: 69.3 mg/mL (132.35 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9098 mL	9.5491 mL	19.0982 mL
5 mM	0.382 mL	1.9098 mL	3.8196 mL
10 mM	0.191 mL	0.9549 mL	1.9098 mL
50 mM	0.0382 mL	0.191 mL	0.382 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ason B, et al. Cardiovascular response to small-molecule APJ activation. JCI Insight. 2020 Apr 23;5(8):e132898.
CHEN NING, et al. TRIAZOLE AGONISTS OF THE APJ RECEPTOR. WO2016187308A1. 11/24/2016.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481